Study BV-MAZOVIA

"Effectiveness and safety of brentuximab vedotin (BV) consolidation therapy in patients with Hodgkin lymphoma (HL) who underwent autologous stem cell transplantation (ASCT). Prospective, multicenter observational study."

NON-INTERVENTIONAL STUDY

Dear Sir/Madam,

We invite you to participate in a multicenter observational study entitled:

Effectiveness and safety of brentuximab vedotin (BV) consolidation therapy in patients with Hodgkin lymphoma (HL) who underwent autologous stem cell transplantation (ASCT). Prospective, multicenter observational study, which aims to determine progression-free survival (PFS) and the clinical and demographic characteristics of patients with Hodgkin lymphoma (HL), including best response to first-line treatment, time to progression, and predictors of high risk of progression.

To start the study, it is necessary to conclude an online agreement. Therefore, please register and follow the instructions appearing on the computer screen.

After successful registration and signing of the electronic agreement, please log in with the data obtained during the account creation process.

BioStat® company ensures smooth conduct of the study and data analysis.

Please direct any questions to the Organizer's office.

BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
tel: 530 714 118
email: [email protected]

VV-MEDMAT-51167

Please fill in the registration form and join the study.

Registration form

Study sponsor

Takeda Pharma sp. z o.o.
Prosta 68, 00-838 Warsaw
tel: +48 22 608 13 00/01
fax: +48 22 608 13 03

Please log in with the data obtained after signing the online agreement.

Login
Hasło